A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan

NCT07730489 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: BL-M07D1
DRUG: Regorafenib
DRUG: Fruquintinib
DRUG: TAS-102

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]